ATE175211T1 - Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp) - Google Patents

Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)

Info

Publication number
ATE175211T1
ATE175211T1 AT91115079T AT91115079T ATE175211T1 AT E175211 T1 ATE175211 T1 AT E175211T1 AT 91115079 T AT91115079 T AT 91115079T AT 91115079 T AT91115079 T AT 91115079T AT E175211 T1 ATE175211 T1 AT E175211T1
Authority
AT
Austria
Prior art keywords
frog
cnp
biologically active
derived peptide
new biologically
Prior art date
Application number
AT91115079T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Suntory Ltd
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd, Hisayuki Matsuo filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE175211T1 publication Critical patent/ATE175211T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
AT91115079T 1990-09-07 1991-09-06 Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp) ATE175211T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238294A JP2977159B2 (ja) 1990-09-07 1990-09-07 カエル由来新規生理活性ペプチド（カエルｃｎｐ）

Publications (1)

Publication Number Publication Date
ATE175211T1 true ATE175211T1 (de) 1999-01-15

Family

ID=17028056

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91115079T ATE175211T1 (de) 1990-09-07 1991-09-06 Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)

Country Status (8)

Country Link
US (1) US5336759A (de)
EP (1) EP0475290B1 (de)
JP (1) JP2977159B2 (de)
AT (1) ATE175211T1 (de)
DE (1) DE69130695T2 (de)
DK (1) DK0475290T3 (de)
ES (1) ES2127189T3 (de)
GR (1) GR3029632T3 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP4825667B2 (ja) 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
JP4972403B2 (ja) 2004-03-31 2012-07-11 一和 中尾 身長増加用組成物
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
JP2010539059A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 例えばＡＩＤＳまたはアルツハイマーの治療のための治療剤としてのβ−メラノトロピンの使用
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CN107405390A (zh) 2014-12-05 2017-11-28 阿雷克森制药公司 用重组碱性磷酸酶治疗癫痫
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
WO2017031114A1 (en) 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (de) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. Behandlung von muskelschwäche mit alkalischen phosphatasen
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573A4 (de) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
BR112019020506A2 (pt) 2017-03-31 2020-08-04 Alexion Pharmaceuticals, Inc. métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes
EP3773684A1 (de) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Herstellung von glycoproteinen
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
JPH04120095A (ja) 1992-04-21
EP0475290B1 (de) 1998-12-30
DE69130695T2 (de) 1999-06-10
DE69130695D1 (de) 1999-02-11
JP2977159B2 (ja) 1999-11-10
DK0475290T3 (da) 1999-08-30
US5336759A (en) 1994-08-09
ES2127189T3 (es) 1999-04-16
GR3029632T3 (en) 1999-06-30
EP0475290A1 (de) 1992-03-18

Similar Documents

Publication Publication Date Title
ATE175211T1 (de) Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)
DE69130696D1 (de) Ein neues, biologisch aktives vom Huhn stammendes Peptid (Huhn-CNP)
ATE145914T1 (de) Anticonvulsive fructopyranose zyklische sulfate und sulfite
DE68921850D1 (de) Reinigung von durch Verwendung von Doppelmetallcyanidkomplexkatalysatoren hergestellten Polyolen.
IT8921742A0 (it) Procedimento per la purificazione delle acque reflue prodotte dagli impianti di produzione dell'urea.
DK0696937T3 (da) Fremgangsmåde til behandling af spontant forbrændelige katalysatorer
FI885504A (fi) Vaskulaera antikoagulerande proteiner, dessa koderande dna, deras framstaellningsfoerfarande och deras anvaendning.
ATE39249T1 (de) Verfahren zur herstellung von polyisocyanatopolyisocyanuraten durch katalytische cyclotrimerisierung von polyisocyanaten.
DE69219590D1 (de) BPC-Peptide, deren Herstellung und Verwendung
PT641215E (pt) Analogos de trombomodulina resistentes a proteases
DE69010442D1 (de) Reinigung von 1,1-Dichlor-1-fluorethan.
DK0407212T3 (da) Enantioselektiv syntese af antifolater
ATE305044T1 (de) Lgmd- gen kodierend für einer calcium abhängigen protease
DE69116803D1 (de) Peroxidase-Gen von mikrobischem Ursprung
DE59602774D1 (de) Verfahren zur Herstellung von 3.3.5-Trimethylcyclohexanon
ATE209683T1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
ATE92077T1 (de) Enzymhemmer und methode zu dessen herstellung.
IT8941638A0 (it) Procedimento ed impianto per il recupero di bitartrato di potassio dalle acque reflue di rigenerazione di impianti di deionizzazione del mosto d'uva.
ATE49964T1 (de) Benzodioxepane, verfahren zur herstellung und verwendung als heilmittel.
IT8423089A1 (it) Solubilizzazione di ossigeno mediante adsorbimento dell'ossigeno nei fanghi biologici degli impianti di depurazione a fanghi attivi
IT9047825A0 (it) Impianto prefabbricato per il procedimento di trattamento di depurazione di liquami fognari cittadini, o scarichi industriali.
DE69325637D1 (de) Herstellung von Copolymeren aus Kohlenmonoxid und ethylenisch ungesättigten Verbindungen
SE8403252D0 (sv) Forfarande vid forbrenning, jemte brensle
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee